PIOPED II also highlighted the affect of pretest clinical probability around the predictive price of CTPA. A normal CTPA experienced a substantial adverse predictive benefit for PE at 96% and 89% in individuals with a low or intermediate scientific probability, respectively, but its negative predictive price was only 60% When the pretest likelihood